Omeros Logo     Print Page  |  Close Window

Investor Relations Home

Due to an error by our third-party webcasting provider, the live webcast on August 9 was disconnected for approximately three minutes during the Q&A segment. However, the complete webcast is available for replay on demand.

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$16.08
Change (%) Stock is Up 0.07 (0.44%)
Volume304,983
Data as of 04/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
04/03/17Omeros to Present at the Needham Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Apr. 3, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16th Annual Needham Healthcare Conference in New York City this week. The presentation is scheduled for Wednesday, April 5, 2017 at 12:10 p.m. EDT. The presentation will be webcast. The live and archived webcasts can be accessed on the “Events” page of the comp... 
 Printer Friendly Version
03/30/17Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases
-- Phase 3 Program Slated for This Year -- SEATTLE--(BUSINESS WIRE)--Mar. 30, 2017-- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, which frequently lead to end-stage renal disease and dialysis. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the e... 
 Printer Friendly Version
03/28/17Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation
-- Additional Positive “Challenge-Rechallenge” Data Reported in Patient with Stem Cell Transplant-Associated TMA -- SEATTLE--(BUSINESS WIRE)--Mar. 28, 2017-- Omeros Corporation (NASDAQ: OMER) today announced presentation of a case report describing resolution of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a dialysis- and transfusion-dependent adolescent girl who was treated with OMS721 under a compass... 
 Printer Friendly Version
03/27/17Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
SEATTLE, Wash.--(BUSINESS WIRE)--Mar. 27, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data from the dose-ranging stage of the Phase 2 clinical trial evaluating OMS721 in the treatment of atypical hemolytic uremic syndrome (aHUS) will be presented next month at the International Society of Nephrology’s World Congress of Nephrology in Mexico City. The poster presentation, “Dose-Finding Clinical Trial of OMS721 for the Treatment of Atypica... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2015 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.